Plus Therapeutics Rebrands as Cerenome, Shifts Focus to Integrated CNS Oncology — Plus Therapeutics, Inc.

Event summary

Plus Therapeutics completes rebrand to Cerenome, effective August 3, 2026.
New ticker symbol 'CNSY' begins trading on Nasdaq Capital Market the same day.
Company integrates precision diagnostics (CNSide®), targeted therapeutics (REYOBIQ™), and AI data analytics into a unified CNS oncology platform.
Rebrand reflects strategic shift from therapeutics-focused to integrated multimodal approach for CNS cancers.

The big picture

Cerenome's rebrand underscores a broader industry trend toward holistic cancer care platforms that combine diagnostics, therapeutics, and data analytics. The shift reflects growing recognition that CNS oncology requires multimodal solutions to address the complexity of these diseases. With its integrated approach, Cerenome aims to position itself as a one-stop shop for CNS cancer detection, treatment, and monitoring, potentially attracting partners and investors seeking comprehensive solutions.

What we're watching

Integration Execution: How Cerenome will synchronize its diagnostic, therapeutic, and AI platforms to deliver meaningful clinical outcomes.
Market Differentiation: Whether the integrated platform can establish a competitive edge in the crowded CNS oncology space.
Regulatory Pathways: The pace at which REYOBIQ™ advances through clinical trials and secures approvals for leptomeningeal metastases, glioblastoma, and pediatric brain cancers.